MedTrace Logo

Effect of Pioglitazone on Insulin Resistance and Atherosclerosis in Renal Allograft Recipients Without Diabetes

NCT00598013 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2008-01-18

No results posted yet for this study

Summary

The aim of this study was to evaluate the effect of pioglitazone treatment on insulin secretion, insulin resistance, and progression of atherosclerosis in renal allograft recipients without preoperative history of diabetes.

Conditions

Interventions

DRUG

Pioglitazone

The pioglitazone treatment group received 30mg pioglitazone at 2 weeks after renal transplantation for 12 months.

Sponsors & Collaborators

  • Yonsei University

    lead OTHER

Principal Investigators

  • Hyun Chul Lee, Doctor · Yonsei University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-11-30
Primary Completion
2007-11-30
Completion
2007-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00598013 on ClinicalTrials.gov